Literature DB >> 33525753

Zoledronate Causes a Systemic Shift of Macrophage Polarization towards M1 In Vivo.

Manuel Weber1, Andi Homm1, Stefan Müller1, Silke Frey2, Kerstin Amann3, Jutta Ries1, Carol Geppert4, Raimund Preidl1, Tobias Möst1, Peer W Kämmerer5, Marco Kesting1, Falk Wehrhan1.   

Abstract

BACKGROUND: Immunomodulatory properties of bisphosphonates (BP) are suggested to contribute to the development of medication-associated osteonecrosis of the jaw (MRONJ). Furthermore, bisphosphonate-derived immune modulation might contribute to the anti-metastatic effect observed in breast cancer patients. Macrophages are potential candidates for the mediation of immunomodulatory effects of bisphosphonates. The study aimed to investigate the influence of bisphosphonates alone and in combination with surgical trauma on systemic macrophage polarization (M1 vs. M2) using an in vivo rat model.
METHODS: A total of 120 animals were divided into four groups. Groups 2 and 4 were treated with 8 × 40 μg/kg body weight of the BP Zoledronate i.p. (week 0-7). Groups 3 and 4 were exposed to surgical trauma (week 8, tooth extraction + tibia fracture), whereas in Group 1 neither medication nor surgical trauma was applied. After 8, 10, 12 and 16 weeks, skin, lung and spleen were immunohistochemically examined for macrophage polarization via expression analysis of CD68, CD163 and iNOS using a tissue microarray (TMA).
RESULTS: A significant shift of macrophage polarization towards M1 was observed in skin, spleen and lung tissue of animals, with and without surgical trauma, treated with BP when compared to those without BP application. Surgical trauma did not cause a significant increase towards M1 polarization.
CONCLUSIONS: BP application leads to a systemic pro-inflammatory situation in vivo, independent of surgical trauma, as evidenced by the shift in macrophage polarization towards M1 in various somatic tissues. This provides a possible explanation for the clinically observed anti-tumor effect of bisphosphonates and might also contribute to pathogenesis of MRONJ.

Entities:  

Keywords:  M1; M2; Zoledronate; antiresorptives; bisphosphonate; immune modulation; macrophage polarization

Year:  2021        PMID: 33525753      PMCID: PMC7865688          DOI: 10.3390/ijms22031323

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  50 in total

Review 1.  Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

Authors:  P Hadji; R E Coleman; C Wilson; T J Powles; P Clézardin; M Aapro; L Costa; J-J Body; C Markopoulos; D Santini; I Diel; A Di Leo; D Cameron; D Dodwell; I Smith; M Gnant; R Gray; N Harbeck; B Thurlimann; M Untch; J Cortes; M Martin; U-S Albert; P-F Conte; B Ejlertsen; J Bergh; M Kaufmann; I Holen
Journal:  Ann Oncol       Date:  2015-12-17       Impact factor: 32.976

2.  Diabetes mellitus negatively affects peri-implant bone formation in the diabetic domestic pig.

Authors:  Cornelius von Wilmowsky; Philipp Stockmann; Igor Harsch; Kerstin Amann; Philipp Metzler; Rainer Lutz; Tobias Moest; Friedrich Wilhelm Neukam; Karl Andreas Schlegel
Journal:  J Clin Periodontol       Date:  2011-08       Impact factor: 8.728

Review 3.  Monocyte and macrophage plasticity in tissue repair and regeneration.

Authors:  Amitava Das; Mithun Sinha; Soma Datta; Motaz Abas; Scott Chaffee; Chandan K Sen; Sashwati Roy
Journal:  Am J Pathol       Date:  2015-06-26       Impact factor: 4.307

Review 4.  Macrophage plasticity and polarization in tissue repair and remodelling.

Authors:  Alberto Mantovani; Subhra K Biswas; Maria Rosaria Galdiero; Antonio Sica; Massimo Locati
Journal:  J Pathol       Date:  2012-11-29       Impact factor: 7.996

5.  Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment.

Authors:  F Wehrhan; P Hyckel; K Amann; J Ries; P Stockmann; Ka Schlegel; Fw Neukam; E Nkenke
Journal:  Oral Dis       Date:  2011-03-02       Impact factor: 3.511

6.  BRONJ-related jaw bone is associated with increased Dlx-5 and suppressed osteopontin-implication in the site-specific alteration of angiogenesis and bone turnover by bisphosphonates.

Authors:  Falk Wehrhan; Kerstin Amann; Patrick Möbius; Manuel Weber; Raimund Preidl; Jutta Ries; Phillip Stockmann
Journal:  Clin Oral Investig       Date:  2014-12-03       Impact factor: 3.573

7.  The enhancing effect of a laser photochemotherapy with cisplatin or zolendronic acid in primary human osteoblasts and osteosarcoma cells in vitro.

Authors:  Paul Günther Baptist Heymann; Thomas Ziebart; Peer Wolfgang Kämmerer; Robert Mandic; Akram Saydali; Andreas Braun; Andreas Neff; Guy Florian Draenert
Journal:  J Oral Pathol Med       Date:  2016-04-28       Impact factor: 4.253

8.  Osteoclast profile of medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis.

Authors:  Christian Gross; Manuel Weber; Kay Creutzburg; Patrick Möbius; Raimund Preidl; Kerstin Amann; Falk Wehrhan
Journal:  J Transl Med       Date:  2017-06-06       Impact factor: 5.531

9.  Osteoclastic expression of higher-level regulators NFATc1 and BCL6 in medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis.

Authors:  Falk Wehrhan; Christian Gross; Kay Creutzburg; Kerstin Amann; Jutta Ries; Marco Kesting; Carol-Immanuel Geppert; Manuel Weber
Journal:  J Transl Med       Date:  2019-03-04       Impact factor: 5.531

10.  Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany.

Authors:  Ingo Diel; Sonja Ansorge; David Hohmann; Christina Giannopoulou; Daniela Niepel; Michele Intorcia
Journal:  Support Care Cancer       Date:  2020-02-21       Impact factor: 3.603

View more
  3 in total

1.  A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients.

Authors:  Seoyeon Jung; Jaeyeon Kim; Jin Hoo Park; Ki-Yeol Kim; Hyung Jun Kim; Wonse Park
Journal:  Sci Rep       Date:  2022-05-23       Impact factor: 4.996

Review 2.  Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  J I Aguirre; E J Castillo; D B Kimmel
Journal:  Bone       Date:  2021-09-11       Impact factor: 4.398

3.  A Mathematical Model of In Vitro Cellular Uptake of Zoledronic Acid and Isopentenyl Pyrophosphate Accumulation.

Authors:  Elena Lo Presti; Laura D'Orsi; Andrea De Gaetano
Journal:  Pharmaceutics       Date:  2022-06-14       Impact factor: 6.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.